A newly launched UK biotech is looking to develop a new approach to immunotherapy, based around a seemingly paradoxical idea that stimulating cancer makes them more visible to the body’s de
Bristol-Myers Squibb is hoping to drive forward its Opdivo cancer immunotherapy franchise by finding a better biomarker than PD-L1 - and has just produced encouraging results in a trial loo
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.